Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Orlando, Florida Clinical Trials

A listing of Orlando, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (172) clinical trials

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the ...

Phase

0.0 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

Phase

0.0 miles

Learn More »

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

Phase

0.0 miles

Learn More »

BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder

The purpose of this study is to compare the efficacy of BHV-4157 versus placebo in subjects with Obsessive Compulsive Disorder (OCD).

Phase

0.0 miles

Learn More »

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

The primary objective of this study is to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Phase

0.0 miles

Learn More »

Study for Pediatric ADHD Learning that your 4 or 5 year old child has attention-deficit/hyperactivity disorder (ADHD) is challenging. It may leave you wondering what options are available for your child and whether they will be safe for your child at such a young age.  New clinical research studies will ...

Phase N/A

0.22 miles

Learn More »

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

The study will consist of a Screening Period, a Dose Optimization Phase, and a Treatment Phase and a Follow-Up Visit, as follows: Screening Period: Subjects will undergo a screening period up to 30 days prior to entering the Dose Optimization Phase. Dose Optimization Phase: During the Dose Optimization Phase, subjects ...

Phase

0.22 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of SEP-363856 flexibly dosed at 25, 50, or 75 mg/day for 6 weeks in male and female subjects 55 years of age with a clinical diagnosis of PDP. The study will randomize approximately 36 subjects ...

Phase

0.41 miles

Learn More »

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

This is an event driven study to reach statistical power given all other assumptions. Subjects will visit the clinic 1 month after randomization and at regular intervals thereafter. Additionally, for any subject prematurely discontinuing study medication, assessments will be conducted every 6 months for the collection of study endpoints. Those ...

Phase

0.41 miles

Learn More »

A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in patients with Stage III or IV ovarian cancer. Patients must have completed front-line platinum based regimen with a physician-assessed response of Complete Response (CR) or Partial Response (PR). Additionally, patients must have a normal or >90% decrease in cancer ...

Phase

0.41 miles

Learn More »